Seoul, South Korea Saturday, March 29, 2025, 14:00 Hrs [IST] ...

In the study, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) reduced the risk of radiographic progression or death by 59% ...

FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with ...

Chinese biotech start-ups are going up against Western drug makers - and they could win A decade ago, treating cancer with personalised mRNA vaccines seemed like a US$1 million gamble per patient, a ...